Pharma RSS Digest - 2026-05-06
Overview
Tuesday's pharma news flow was light, featuring two mid-stage catalysts in niche indications with meaningful unmet need. Cellenkos secured FDA clearance to advance CK0802, an off-the-shelf regulatory T cell therapy, into a Phase 1b/2a trial for steroid-refractory graft-versus-host disease—a condition where roughly half of transplant patients fail steroids and two-year survival hovers around 30%. Separately, Alebund Pharmaceuticals completed enrollment in a global pivotal trial for AP301, a fiber-iron-based phosphate binder, with the FDA agreeing that a single trial can support US registration—an efficiency play in a market where the majority of dialysis patients remain above target phosphate levels. Both stories reflect continued deal flow and trial activity in Orphan indications, though neither represents a near-term commercial milestone.
Key Developments
Cellenkos Clears FDA Hurdle for CK0802 in Refractory GVHD Cellenkos announced FDA clearance of its Investigational New Drug application for CK0802, a cord-blood derived regulatory T cell therapy, enabling the company to initiate a multicenter Phase 1b/2a trial in patients with steroid-refractory graft-versus-host disease following allogeneic stem cell transplant. The trial will evaluate safety and overall response rate at Day 29, with enrollment beginning in the second half of 2026 and a clinical readout expected in early 2027. The therapy works through multiple anti-inflammatory mechanisms—including IL-10 release and IL-2 consumption—to suppress the aberrant immune activation driving GVHD. This milestone validates Cellenkos' CRANE manufacturing platform and represents a potential step forward for a patient population with dismal outcomes and limited alternatives; prior Phase 1 data in COVID-19 ARDS showed promising survival signals, though efficacy in actual GVHD patients remains unproven. Watch for trial-site activation updates and any guidance on enrollment pace as 2026 progresses.
Alebund Completes Enrollment for AP301 Pivotal Trial in Hyperphosphatemia Alebund Pharmaceuticals announced completion of patient enrollment in RESPOND-2, a global Phase III pivotal trial evaluating AP301—a fiber-iron-based phosphate binder—in 282 CKD patients on dialysis across the US and China. The FDA previously agreed that this single multinational trial would serve as the pivotal study supporting US registration, a notable efficiency given the typical dual-trial requirement for chronic kidney disease therapies. A prior China pivotal trial demonstrated AP301 was non-inferior to sevelamer carbonate at Week 12, with similar serum phosphate reductions. Hyperphosphatemia affects approximately 95% of dialysis-dependent CKD patients and is an independent risk factor for cardiovascular mortality, yet current binder options carry limitations including gastrointestinal side effects, pill burden, and iron overload concerns. The AP301 formulation is designed to address these gaps with better tolerability and no chewing required, potentially improving adherence in a population with notoriously poor compliance. With enrollment complete, the next inflection point will be the Week 12 data readout and subsequent regulatory submissions.
Alebund Pharmaceuticals clinical trial update
Watchlist
- No additional items identified in today's digest run.